Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of BCDIN3D knock-out on gene expression in Chronic Myelogenous Leukemia (CML) Hap1 cells.

ABSTRACT: Effect of BCDIN3D knock-out on gene expression in Chronic Myelogenous Leukemia (CML) Hap1 cells.

PROVIDER: PRJNA525893 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR8692170_1.fastq.gz	Fastqsanger.gz
	SRR8692170_2.fastq.gz	Fastqsanger.gz
	SRR8692171_1.fastq.gz	Fastqsanger.gz
	SRR8692171_2.fastq.gz	Fastqsanger.gz
	SRR8692172_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Effect of BCDIN3D knock-out on gene expression in Chronic Myelogenous Leukemia (CML) Hap1 cells.

Project description:WT and BCDIN3D knocked-out Hap1 cells were analysed by RNA- and microRNA-Seq to uncover the effect of BCDIN3D on specific microRNAs and their messenger RNA targets.

2022-03-06 | GSE127973 | GEO

Role of Gdpd3 in chronic myelogenous leukemia stem cells

Project description:We examined gene expression profiling in long-term chronic myelogenous leukemia (CML) stem cells isolated from Gdpd3+/+ and Gdpd3-/- CML mouse model by RNA sequence.

2020-08-18 | GSE149442 | GEO

Next Generation Sequencing Facilitates Quantitative Analysis of control, SETD6 Knock-out, SETD3 knock-out and SETD6+SETD3 knock-out HeLa cells Transcriptomes

Project description:Next Generation Sequencing Facilitates Quantitative Analysis of control, SETD6 Knock-out, SETD3 knock-out and SETD6+SETD3 knock-out HeLa cells Transcriptomes

| PRJNA819059 | ENA

ARRDC4 knock out Mouse Heart Analysis

Project description:ARRDC4 knock out Mouse Heart Analysis

| PRJNA773414 | ENA

Moore_2004_Mathematical model for CML and T cell interaction

Project description:Its a mathematical model depicting CML (chronic myelogenous leukemia) interaction with T cells and impact of T cell activations on CML progression over time.

2024-09-02 | BIOMD0000000733 | BioModels

Expression data in patients with chronic myelogenous leukemia for response to imatinib

Project description:This is a class prediction experiment, where the class is the response status to imatinib (also called Gleevec), a drug used to treat patients with chronic myelogenous leukemia (CML). There are two data sets, a training set (from Leipzig, 8 Responders and 5 Non-Responders) and a validation set (from Mannheim, 8 Responders and 7 Non-Responders). The objective is to identify differentially regulated genes between CML patients who respond and those who do not respond to imatinib and confirm the results in the validation data set. The samples from blood or bone marrow of CML patients were hybridized to Affymetrix HG-U95Av2 chip and RMA was used to generate the normalized signal values. Keywords = chronic myelogenous leukemia Keywords = imatinib Keywords = cytogenetic responses Keywords = Gleevec Keywords = Affymetrix Keywords: other

2005-04-18 | GSE2535 | GEO

Imatinib and Nilotinib induced molecular changes in Philadelphia chromosome-positive Chronic Myelogenous Leukemia

Project description:Chronic myelogenous leukemia (CML) is a malignant stem cell disease characterized by a reciprocal translocation between chromosome 9 and 22. The selective bcr-abl tyrosine-kinase inhibitor Imatinib has become the therapy of choice for patients with newly diagnosed CML including those previously considered candidates for allogeneic haematopoietic stem cell transplantation. The tyrosine-kinase inhibitor Nilotinib is a derivate of Imatinib with higher potency. To examine the molecular and functional effects of Nilotinib and Imatinib in chronic myelogenous leukemia, we performed gene expression and functional analyses in K562 cells following treatment with the two tyrosine kinase inhibitors.

2009-12-19 | GSE19567 | GEO

Gene expression profiling of pre-HPCs derived from CML-iPSCs

Project description:Properties of cancer stem cells (CSC) involved in drug-resistance and relapse have significant effect on clinical outcome. Although tyrosine kinase inhibitors (TKIs) have dramatically improved survival of patients with chronic myelogenous leukemia (CML), TKIs have not fully cure CML due to TKI-resistant CML stem cells. Moreover, the relapse after discontinuation of TKIs has not been predicted in CML patients with best TKI-response. In our study, pre-hematoopoietic progenitor cells (pre-HPCs), a model of CML stem cells derived from CML-iPSCs identified a novel antigen of TKI-resistant CML cells. Even in the fraction reported as TKI-sensitive, the antigen+ cells showed TKI-resistance in CML patients. In addition, residual CML cells in patients with optimal TKI-response were concentrated in the antigen+ population.

2016-12-21 | GSE92624 | GEO

anaerobic knock-out

Project description:Six different knock-out strains' expression data under anaerobic condition Keywords: parallel sample

2004-03-10 | GSE1107 | GEO

aerobic knock-out

Project description:Six different knock-out strains' expression data under aerobic condition Keywords: parallel sample

2004-03-10 | GSE1106 | GEO